A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch C, Roth B, Bosshard P, Püschel H, Boll D, Hefermehl L, Roghmann F, Gierth M, Ribi K, Schäfer S, Wicki A, Bubendorf L, Torpai R, Thalmann G, Lucca I, Kwiatkowski M, Wirth G, Strebel R, Engeler D, Pedrazzini A, Hüttenbrink C, Schultze-Seemann W, Hayoz S. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. Eur Urol Oncol 2022; 5:195-202.
Jan 7, 2022
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Jan 7, 2022
Eur Urol Oncol 2022; 5:195-202
Rentsch Cyrill A, Roth Beat, Bosshard Piet, Püschel Heike, Boll Daniel T, Hefermehl Lukas, Roghmann Florian, Gierth Michael, Ribi Karin, Schäfer Simon, Wicki Andreas, Bubendorf Lukas, Torpai Raimund, Thalmann George N, Lucca Ilaria, Kwiatkowski Maciej, Wirth Grégory J, Strebel Räto T, Engeler Daniel, Pedrazzini Augusto, Hüttenbrink Clemens, Schultze-Seemann Wolfgang, Hayoz Stefanie
more
